Literature DB >> 17178760

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.

M K de Vries, G J Wolbink, S O Stapel, E R de Groot, B A C Dijkmans, L A Aarden, I E van der Horst-Bruinsma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17178760      PMCID： PMC1798422          DOI： 10.1136/ard.2006.057745

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  5 in total

Review 1.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors:  J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

2.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.

Authors:  Gerrit Jan Wolbink; Marijn Vis; Willem Lems; Alexandre E Voskuyl; Els de Groot; Michael T Nurmohamed; Steven Stapel; Paul P Tak; Lucien Aarden; Ben Dijkmans
Journal:  Arthritis Rheum       Date:  2006-03

3.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

4.  Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).

Authors:  Désirée van der Heijde; Ben Dijkmans; Piet Geusens; Joachim Sieper; Kimberly DeWoody; Paul Williamson; Jürgen Braun
Journal:  Arthritis Rheum       Date:  2005-02

5.  Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

Authors:  J Braun; X Baraliakos; J Brandt; J Listing; A Zink; R Alten; G Burmester; E Gromnica-Ihle; H Kellner; M Schneider; H Sörensen; H Zeidler; J Sieper
Journal:  Rheumatology (Oxford)       Date:  2005-03-09       Impact factor: 7.580
  5 in total
  17 in total

Review 1.  Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.

Authors:  Narendra Chirmule; Vibha Jawa; Bernd Meibohm
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

2.  Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis.

Authors:  José Miguel Senabre Gallego; Jose Rosas; Mariana Marco-Mingot; José Alberto García-Gómez; Gregorio Santos-Soler; Esteban Salas-Heredia; Ana Pons-Bas; Xavier Barber-Vallés; José Antonio Bernal-Vidal; Catalina Cano-Pérez; Mario García-Carrasco; Emilio Flores-Pardo
Journal:  Rheumatol Int       Date:  2019-03-21       Impact factor: 2.631

3.  Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.

Authors:  Hilbert S de Vries; Martijn G H van Oijen; Rieke J B Driessen; Elke M G J de Jong; Marjonne C W Creemers; Wietske Kievit; Dirk J de Jong
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

4.  Update on biologic therapy in the management of axial spondyloarthritis.

Authors:  Frank Heldmann; Friedrich Dybowski; Ertan Saracbasi-Zender; Claas Fendler; Jürgen Braun
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

5.  Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.

Authors:  Mirjam K de Vries; Gerrit Jan Wolbink; Steven O Stapel; Henk de Vrieze; J Christiaan van Denderen; Ben A C Dijkmans; Lucien A Aarden; Irene E van der Horst-Bruinsma
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

Review 6.  Biological therapies for spondyloarthritis.

Authors:  Vincenzo Bruner; Mariangela Atteno; Angelo Spanò; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-06       Impact factor: 5.346

Review 7.  Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

Authors:  Joachim R Kalden; Hendrik Schulze-Koops
Journal:  Nat Rev Rheumatol       Date:  2017-11-21       Impact factor: 20.543

Review 8.  Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.

Authors:  Katherine L Gill; Krishna K Machavaram; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

Review 9.  The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics.

Authors:  Juan Jose Perez Ruixo; Peiming Ma; Andrew T Chow
Journal:  AAPS J       Date:  2012-11-10       Impact factor: 4.009

10.  Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.

Authors:  Inesa Arstikyte; Giedre Kapleryte; Irena Butrimiene; Algirdas Venalis
Journal:  Biomed Res Int       Date:  2015-04-27       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.